Ask sales for the lot-numbered COA matched to the offered or supplied batch; it records the tests actually completed, their specifications, and the reported results.

Matching batch COA available.

PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →

FDA PCAC reviews 7 peptides in July. Read →

Repair Peptides

BPC-157, TB-500 and related repair-focused peptides for tendon, gastrointestinal mucosa, and soft-tissue research applications.

15-mer

BPC-157

≥99.0%

Body Protection Compound 15-mer

CAS: 137525-51-0
Vial: 2 mg–20 mg

MOQ on requestGet quote →

43-mer

TB-500

≥99.0%

Thymosin β4 fragment

CAS: 77591-33-4
Vial: 2 mg–10 mg

MOQ on requestGet quote →

PEG MGF

≥99.0%

PEGylated Mechano Growth Factor

CAS: 108174-48-7; architecture confirmed on batch COA
Vial: 2 mg

MOQ on requestGet quote →

27-mer

B7-33

≥99.0%

Single-chain relaxin analog · RXFP1 agonist

CAS: 1818415-56-3
Vial: 2 mg · 10 mg

By requestGet quote →

Applications & buyer fit

What this class is sourced for, and who buys it

Repair peptides, BPC-157, TB-500, and related sequences, typically ship to research labs studying tissue-repair, gastrointestinal, or tendon-ligament models. Ask sales for the COA matched to the offered or supplied lot. If the buyer's written qualification procedure requires tandem-MS sequence evidence, include it in the agreed scope before quotation rather than treating it as an automatic first-batch retest.

Buyer types across this category

503A / 503B compounding pharmacies
academic and contract research laboratories

See how batch documentation works

Documentation available for this class

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Sequence verification (LC-MS/MS)
Water content (Karl Fischer)
Counter-ion analysis
SDS / MSDS
Stability data on request

Sold for research and commercial use under the buyer's local regulations. Not a finished dosage form and not labeled for human administration as shipped. Repair-class peptides are not approved drug products in most jurisdictions and should be handled accordingly in research, manufacturing, and reporting.